Literature DB >> 17640906

The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.

Kitt Falk Petersen1, Sylvie Dufour, David B Savage, Stefan Bilz, Gina Solomon, Shin Yonemitsu, Gary W Cline, Douglas Befroy, Laura Zemany, Barbara B Kahn, Xenophon Papademetris, Douglas L Rothman, Gerald I Shulman.   

Abstract

We examined the hypothesis that insulin resistance in skeletal muscle promotes the development of atherogenic dyslipidemia, associated with the metabolic syndrome, by altering the distribution pattern of postprandial energy storage. Following ingestion of two high carbohydrate mixed meals, net muscle glycogen synthesis was reduced by approximately 60% in young, lean, insulin-resistant subjects compared with a similar cohort of age-weight-body mass index-activity-matched, insulin-sensitive, control subjects. In contrast, hepatic de novo lipogenesis and hepatic triglyceride synthesis were both increased by >2-fold in the insulin-resistant subjects. These changes were associated with a 60% increase in plasma triglyceride concentrations and an approximately 20% reduction in plasma high-density lipoprotein concentrations but no differences in plasma concentrations of TNF-alpha, IL-6, adiponectin, resistin, retinol binding protein-4, or intraabdominal fat volume. These data demonstrate that insulin resistance in skeletal muscle, due to decreased muscle glycogen synthesis, can promote atherogenic dyslipidemia by changing the pattern of ingested carbohydrate away from skeletal muscle glycogen synthesis into hepatic de novo lipogenesis, resulting in an increase in plasma triglyceride concentrations and a reduction in plasma high-density lipoprotein concentrations. Furthermore, insulin resistance in these subjects was independent of changes in the plasma concentrations of TNF-alpha, IL-6, high-molecular-weight adiponectin, resistin, retinol binding protein-4, or intraabdominal obesity, suggesting that these factors do not play a primary role in causing insulin resistance in the early stages of the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640906      PMCID: PMC1924794          DOI: 10.1073/pnas.0705408104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

Authors:  Jay D Horton; Joseph L Goldstein; Michael S Brown
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men.

Authors:  Kitt Falk Petersen; Sylvie Dufour; Jing Feng; Douglas Befroy; James Dziura; Chiara Dalla Man; Claudio Cobelli; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

3.  Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects.

Authors:  T E Graham; C J Wason; M Blüher; B B Kahn
Journal:  Diabetologia       Date:  2007-02-09       Impact factor: 10.122

4.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance.

Authors:  J K Kim; J J Fillmore; Y Chen; C Yu; I K Moore; M Pypaert; E P Lutz; Y Kako; W Velez-Carrasco; I J Goldberg; J L Breslow; G I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

5.  Carbohydrate balance predicts weight and fat gain in adults.

Authors:  Robert H Eckel; Teri L Hernandez; Melanie L Bell; Kathleen M Weil; Trudy Y Shepard; Gary K Grunwald; Teresa A Sharp; Coni C Francis; James O Hill
Journal:  Am J Clin Nutr       Date:  2006-04       Impact factor: 7.045

6.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Authors:  Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

7.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Authors:  Kitt Falk Petersen; Elif Arioglu Oral; Sylvie Dufour; Douglas Befroy; Charlotte Ariyan; Chunli Yu; Gary W Cline; Alex M DePaoli; Simeon I Taylor; Phillip Gorden; Gerald I Shulman
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

8.  Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Amy Wang; Sara A Beddow; John G Geisler; Mario Kahn; Xian-man Zhang; Brett P Monia; Sanjay Bhanot; Gerald I Shulman
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

9.  Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle.

Authors:  J K Kim; M D Michael; S F Previs; O D Peroni; F Mauvais-Jarvis; S Neschen; B B Kahn; C R Kahn; G I Shulman
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

10.  Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.

Authors:  David B Savage; Cheol Soo Choi; Varman T Samuel; Zhen-Xiang Liu; Dongyan Zhang; Amy Wang; Xian-Man Zhang; Gary W Cline; Xing Xian Yu; John G Geisler; Sanjay Bhanot; Brett P Monia; Gerald I Shulman
Journal:  J Clin Invest       Date:  2006-02-16       Impact factor: 14.808

View more
  241 in total

Review 1.  Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials.

Authors:  Akintunde O Akinkuolie; Julius S Ngwa; James B Meigs; Luc Djoussé
Journal:  Clin Nutr       Date:  2011-09-29       Impact factor: 7.324

Review 2.  The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

Authors:  François R Jornayvaz; Varman T Samuel; Gerald I Shulman
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

3.  The effect of water suppression on the hepatic lipid quantification, as assessed by the LCModel, in a preclinical and clinical scenario.

Authors:  Amandine Coum; Fanny Noury; Elise Bannier; Karima Begriche; Bernard Fromenty; Yves Gandon; Hervé Saint-Jalmes; Giulio Gambarota
Journal:  MAGMA       Date:  2015-11-21       Impact factor: 2.310

4.  Maternal Obesity and Western-Style Diet Impair Fetal and Juvenile Offspring Skeletal Muscle Insulin-Stimulated Glucose Transport in Nonhuman Primates.

Authors:  William Campodonico-Burnett; Byron Hetrick; Stephanie R Wesolowski; Simon Schenk; Diana L Takahashi; Tyler A Dean; Elinor L Sullivan; Paul Kievit; Maureen Gannon; Kjersti Aagaard; Jacob E Friedman; Carrie E McCurdy
Journal:  Diabetes       Date:  2020-04-30       Impact factor: 9.461

5.  The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.

Authors:  Tsuyoshi Goto; Mariko Hirata; Yumeko Aoki; Mari Iwase; Haruya Takahashi; Minji Kim; Yongjia Li; Huei-Fen Jheng; Wataru Nomura; Nobuyuki Takahashi; Chu-Sook Kim; Rina Yu; Shigeto Seno; Hideo Matsuda; Megumi Aizawa-Abe; Ken Ebihara; Nobuyuki Itoh; Teruo Kawada
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

Review 6.  Modulation of hepatic steatosis by dietary fatty acids.

Authors:  Alessandra Ferramosca; Vincenzo Zara
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Reduced physical activity and risk of chronic disease: the biology behind the consequences.

Authors:  Frank W Booth; Matthew J Laye; Simon J Lees; R Scott Rector; John P Thyfault
Journal:  Eur J Appl Physiol       Date:  2007-11-07       Impact factor: 3.078

8.  Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo.

Authors:  Alykhan Motani; Zhulun Wang; Marion Conn; Karen Siegler; Ying Zhang; Qingxiang Liu; Sheree Johnstone; Haoda Xu; Steve Thibault; Yingcai Wang; Pingchen Fan; Richard Connors; Hoa Le; Guifen Xu; Nigel Walker; Bei Shan; Peter Coward
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

9.  Distinct patterns of fat metabolism in skeletal muscle of normal-weight, overweight, and obese humans.

Authors:  S Sendhil Velan; Nicholas Said; Christopher Durst; Stephanie Frisbee; Jefferson Frisbee; Raymond R Raylman; M Albert Thomas; Vazhaikkurichi M Rajendran; Richard G Spencer; Stephen E Alway
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-07-30       Impact factor: 3.619

10.  Lifestyle interventions for the treatment of class III obesity: a primary target for nutrition medicine in the obesity epidemic.

Authors:  George L Blackburn; Samuel Wollner; Steven B Heymsfield
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.